Who are Jardiance's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brenzavvy, Concomitant therapy 14 days, SGLT2 inhibitor, Empagliflozin + Carvedilol, Antihyperglycemic Medication, Dapagliflozin + Lobeglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/empagliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Jardiance — Competitive Intelligence Brief

Jardiance (empagliflozin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC]. Area: Metabolic.

marketed Sodium-Glucose Cotransporter 2 Inhibitor [EPC] SGLT2 Metabolic Live · refreshed every 30 min

Target snapshot

Jardiance (empagliflozin) — Boehringer Ingelheim. SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Jardiance TARGET	empagliflozin	Boehringer Ingelheim	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Concomitant therapy 14 days	Concomitant therapy 14 days	Incheon St.Mary's Hospital	marketed	SGLT2 inhibitor	SGLT2
SGLT2 inhibitor	SGLT2 inhibitor	University of Minnesota	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Empagliflozin + Carvedilol	Empagliflozin + Carvedilol	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	SGLT2 inhibitor + non-selective beta-blocker combination	SGLT2 and beta-adrenergic receptors (β1, β2, α1)
Antihyperglycemic Medication	Antihyperglycemic Medication	Merck Sharp & Dohme LLC	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Dapagliflozin + Lobeglitazone	Dapagliflozin + Lobeglitazone	Seoul National University Bundang Hospital	marketed	SGLT2 inhibitor + thiazolidinedione combination	SGLT2 and PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-Glucose Cotransporter 2 Inhibitor [EPC] class)

· 1 drug in this class
AJANTA PHARMA LTD · 1 drug in this class
AstraZeneca · 1 drug in this class
Boehringer Ingelheim · 1 drug in this class
Lexicon Pharms Inc · 1 drug in this class
Theracosbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Jardiance — Competitive Intelligence Brief. https://druglandscape.com/ci/empagliflozin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab